Genentech to lay off 13% of workforce at California plant

Genentech, a biologics drugmaker owned by Roche, will slash 130 jobs or about 13 percent of its workforce at its Vacaville, Calif. plant as the company faces increased biosimilar competition, according to STAT.

"We are making this organizational change in response to current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments," a Genentech spokeswoman told STAT.

The company will reduce its workforce by the end of the year. 

More articles on supply chain:
6 ways the proposed Republican tax overhaul could impact pharma
3 latest FDA approvals 
FDA: EpiPen failures attributed to 7 deaths this year

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months